Healx
healx.ai
Actively hiring
Machine Learning
Drug Discovery
As featured in
View 1 job
Claim pageClaim
Follow
Overview
News
Technologies
Salaries
Products
People
Growth
Offices
Jobs
Financials
Funding and backers
Total raised
$47M
15 rounds on record
Latest round
Venture round
May 2026 · 4 mo ago
Team
201-500
employees, estimated range
Hiring now
1
open roles
Backers
6
Amadeus Capital Partners, b2venture
The money's age
Fresh money
4 months since the last round · hiring slowed
Momentum
30/100
a new city, fresh money
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
May 29
Raised a round Venture round
Feb 11
Raised a round Venture round
Jul 1, 2025
Partnership Healx and SCI Ventures join forces to uncover cures for paralysis with AI-driven drug discovery · healx.ai
May 6, 2025
New executive Healx Appoints Christopher Moertel as Global Head of Clinical Development · healx.ai
May 1, 2025
Raised a round Venture round
Aug 1, 2024
Certified Healx Announces $47 million Series C Financing and FDA Clearance of Phase 2 IND for Neurofibromatosis Type 1 Trial · healx.ai
Aug 1, 2024
Raised a round Series C $47M · led by R42 Group
Mar 25, 2024
Raised a round Venture round
Nov 11, 2023
Raised a round Venture round
Nov 16, 2022
Raised a round Venture round
Dec 1, 2021
Raised a round Venture round
Apr 7, 2021
Raised a round Venture round
Dec 16, 2020
Raised a round Venture round
Aug 19, 2020
Raised a round Venture round
Oct 17, 2019
Raised a round Venture round
Jul 30, 2018
Raised a round Venture round
Sep 13, 2016
Raised a round Venture round
Apr 1, 2015
Raised a round Venture round
Apr 30, 2014
Founded per the company register
Tractionpublic signals, read monthly
Web presence
top 5%
of 133.2M domains by links, Common Crawl
Funding rounds
Registers and programsofficial lists and records that name the company
| Legal entity | Headquarters Healx Ltd. | its site |
Backed byfrom the funds' portfolios and accelerator catalogs
Amadeus Capital Partners 
b2venture 
Balderton Capital 
Cambridge Angels 
Global Brain 
VU Venture Partners Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Cellarity is a Cambridge biotechnology company founded in 2019 that designs medicines against cell behaviour rather than a single target…
Valo Health is a Boston biotechnology company founded in 2019 that applies computation across drug discovery. Its Opal platform links human…
Plex is the AI-powered scientific intelligence platform for drug discovery. Built on a biomedical knowledge graph with billions of data…
PharmEnable combines medicinal chemistry expertise with machine learning to find drug candidates for challenging protein targets. Founded…
Analyst-grade AI system that answers complex questions across millions of references to optimize drug development and clinical trials.
Discover KolateAI's innovative platform that leverages AI and real-world data to optimize clinical trials and drug development. Empowering…
Overview
Healx is a Cambridge company founded in 2014 that uses artificial intelligence to find treatments for rare diseases. Its knowledge graph combines biomedical literature, drug data and patient information to predict which existing compounds could be repurposed. The company advances its own pipeline of rare disease programmes into clinical trials.
News
Healx Announces First Patient Dosed in Phase 1/2 Trial to Evaluate the Effect of HLX-4310 on Metastatic Recurrence and Progression in Sarcomas with a Focus on Osteosarcoma
Osteosarcoma is a rare, aggressive bone cancer that most often affects children, adolescents, and young adults. Patients who develop metastatic disease face particularly poor outcomes, with a five-year survival rate of less than 30% ¹. The past 40 years h
Read more
Report
Healx Strengthens Focus on Preventing Cancer Recurrence by Leveraging Its AI-Powered Platform and Advancing Its Oncology Pipeline Through a Strategic Transaction with Vuja De Sciences
Healx, the AI-powered biotech company pioneering the next generation of drug discovery for rare diseases, today announced it has entered into a strategic transaction with Vuja De Sciences, a US-based
Read more
Report
Healx Strengthens Focus on Preventing Cancer Recurrence by Leveraging Its AI-Powered Platform and Advancing Its Oncology Pipeline Through a Strategic Transaction with Vuja De Sciences
Healx's proprietary AI platform has uncovered and prioritised therapeutic opportunities across rare diseases and is actively applied in rare and pediatric oncology. The platform is designed to generate and advance Healx's own discovery programs, making it
Read more
Report
Healx and SCI Ventures join forces to uncover cures for paralysis with AI-driven drug discovery
Uniting AI Innovation and Neuroregeneration Expertise This partnership combines the machine learning and drug discovery expertise of Healx with the deep scientific insight, domain expertise, and unique dataset access of SCI Ventures. Backed by leading fou
Read more
Report
Healx Appoints Christopher Moertel as Global Head of Clinical Development
Cambridge, UK, 6 May 2025 - Healx, a leader in AI-driven drug discovery for rare diseases, is pleased to announce the appointment of Christopher Moertel, M.D., as its new Global Head of Clinical Development. Dr. Moertel, a highly respected expert in the f
Read more
Report
Healx Announces First Patient Dosed in Phase 2 Trial Evaluating HLX-1502 for the Treatment of Neurofibromatosis Type 1
NF1 is a debilitating rare genetic disorder that causes tumours to form along nerves, often manifesting in childhood. It affects approximately one in 2,500 individuals worldwide and can lead to severe complications, including pain, disfigurement, and mali
Read more
Report
Jonathan Milner, Ph.D., Appointed as Non-Executive Chairman of Healx
Healx, an AI-enabled, clinical-stage biotech company specialising in rare diseases, today announced the appointment of Jonathan Milner, Ph.D., as the new non-executive chairman of the board, effective immediately. This transition comes as current chairman
Read more
Report
Healx announces agreement with Sanofi to seek new rare disease indications for compound using AI drug discovery platform
Cambridge, UK, November 13, 2024 -Healx, an AI-enabled, clinical-stage biotech company specialising in rare diseases, today announced it will use a Sanofi compound to identify new disease indications using Healnet, Healx's AI-driven drug discovery platfor
Read more
Report
U.S. FDA Grants Fast Track designation for HLX-1502 in Neurofibromatosis Type 1 (NF1) Treatment
Why Fast Track designation Matters The Fast Track designation is awarded by the FDA to facilitate the development and review of drugs that treat serious conditions and fill unmet medical needs. For our team, it means increased interaction with FDA experts
Read more
Report
Healx Announces $47 million Series C Financing and FDA Clearance of Phase 2 IND for Neurofibromatosis Type 1 Trial
Series C round co-led by R42 Group and Atomico, and joined by new/current investors; Financing to advance expanding rare disease pipeline U.S. FDA has cleared its investigational new drug (IND) application to advance HLX-1502 in Phase 2 clinical trial in
Read more
Report
Show more news
Tech stack
Technologies named in job postings at Healx over the last 12 months, by layer, with the share of postings for each.
Technologies in use
13
Postings analysed
3
Stack modernity
72/100AI adopter
Languages
Python
Cloud & platforms
GCP
AI & ML
LLM
Sign in to see how your skills match this stack
Sign In
Full Healx tech stack
13 technologies · by team · pay by technology · changes · similar stacks
Growth
Hiring Momentum
57/100
Growing
Open positions
1
0 opened / 1 closed in 30 days
Median time-to-fill
102 days
faster than 13% of the market
ATS activity
Every ~4 hours
10/21/2026
Hiring Dynamics
+100%
Hiring Focus
The percentage next to each role is its share of the company's job openings over the last 90 days; the arrow shows the shift versus the previous period.
Backend
100% ▼
Activity Timeline
New location: Cambridge
Sep 2026
Added Machine Learning to stack
Sep 2026
Added GCP to stack
Sep 2026
Added Mandiant capa to stack
Sep 2026
Added Agentic Workflows to stack
Sep 2026
Added Model Context Protocol to stack
Aug 2026
Added Google ADK to stack
Aug 2026
Added Function Calling to stack
Aug 2026
Added AI Agents to stack
Aug 2026
Added LLM Evaluation to stack
Aug 2026
Added Knowledge Graph to stack
Aug 2026
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
1
Countries
1
Busiest office
Cambridge
Cambridge
United Kingdom
HQ
1 open roles 1 posted in 90 days 100% engineering 200-500 est. staff
hires for Backend
66-68 Hills Rd, Cambridge, CB2 1LA, UK
Jobs
≈ $50k – $115k per year (Estimated) • Hybrid • Full-Time • 2+ years exp • Cambridge
Python
Model Context Protocol
Function Calling
AI Agents
LLM
RAG
Google ADK
Knowledge Graph
LLM Evaluation
Agentic Workflows
Machine Learning
Apply
Financials
Total raised
$47M
Latest round
Venture - Series Unknown
Funding rounds
15
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Venture - Series Unknown | 2026 | — | Details |
| Venture - Series Unknown | 2026 | — | Details |
| Venture - Series Unknown | 2025 | — | Details |
| Series C | 2024 | $47M | Details |
| Venture - Series Unknown | 2024 | — | Details |
| Venture - Series Unknown | 2023 | — | Details |
| Venture - Series Unknown | 2022 | — | Details |
| Venture - Series Unknown | 2021 | — | Details |
| Venture - Series Unknown | 2021 | — | Details |
| Venture - Series Unknown | 2020 | — | Details |
| Venture - Series Unknown | 2020 | — | Details |
| Venture - Series Unknown | 2019 | — | Details |
| Venture - Series Unknown | 2018 | — | Details |
| Venture - Series Unknown | 2016 | — | Details |
| Venture - Series Unknown | 2015 | — | Details |